Physician profile
Leonard C Altman
NPI 1407892466
$80,755.18
in general payments reported to CMS, 2019-2025
23 companies · $697 in 2025
The $697 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $10K · 2021: $9,354 · 2022: $23K · 2023: $1,936 · 2024: $5,748 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Consulting Fee: $4,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.12 |
| Consulting Fee | $4,134.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $22,718.78 | 2021-2025 | Orladeyo |
| Shire North American Group INC | $18,471.48 | 2019 | |
| Pharming Healthcare, INC. | $12,381.92 | 2019-2025 | Joenja, Ruconest |
| Cardinal Health 110 LLC | $9,450.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,535.77 | 2020-2024 | Takhzyro |
| Astrazeneca Pharmaceuticals Lp | $3,135.74 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Biocryst Pharmaceuticals, INC. | $2,750.00 | 2020 | |
| Genzyme Corporation | $2,028.52 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $284.70 | 2019-2020 | |
| Alk-Abello, INC | $262.62 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Adma Biomanufacturing LLC | $259.79 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $255.39 | 2019-2020 | |
| Genentech, INC. | $238.20 | 2020-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $204.36 | 2021-2025 | Nucala |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $150.90 | 2024 | Ayvakit |
| Genentech USA, INC. | $101.35 | 2024-2025 | Xolair |
| Kaleo, INC. | $73.87 | 2021-2022 | |
| Pfizer INC. | $68.61 | 2021-2023 | |
| Csl Behring | $66.76 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $62.67 | 2021 | |
| Amgen INC. | $23.20 | 2024 | Tezspire |
| Optinose US, INC. | $21.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.